Towards Healthcare
Bioprocess Automation Market Uplifts 12.04% CAGR by 2034

Bioprocess Automation Market Key Drivers and Opportunities

Market insights predict, the bioprocess automation industry is expected to grow from USD 5.4 billion in 2024 to USD 16.88 billion by 2034, driven by a CAGR of 12.04%. The market is growing due to increasing demand for biologics and personalized medicine. Automation improves efficiency, reduces human error, and ensures regulatory compliance. Additionally, advancements in AI and robotics are enhancing process optimization and scalability.

Category: Healthcare IT Insight Code: 5696 Format: PDF / PPT / Excel

The global bioprocess automation market size is calculated at USD 5.4 billion in 2024, grow to USD 6.05 billion in 2025, and is projected to reach around USD 16.88 billion by 2034. The market is expanding at a CAGR of 12.04% between 2025 and 2034.

Bioprocess Automation Market Size 2024 - 2034

Key Takeaways

  • Bioprocess automation sector is pushing the market to USD 5.4 billion in 2024.
  • Long-term projections show USD 16.88 billion valuation by 2034.
  • Growth is expected at a steady CAGR of 12.04% in between 2025 to 2034.
  • North America dominated the bioprocess automation market share in 2024.
  • Asia-Pacific is expected to grow at the highest CAGR in the market during the forecast period.
  • By type of controllers, the upstream controllers segment held the largest revenue market share.
  • By type of controllers, the bioprocess controllers segment is expected to grow at the fastest CAGR in the market during the studied years.
  • By scale of operation, the preclinical segment dominated the market.
  • By scale of operation, the commercial segment is expected to grow at the fastest CAGR in the market during the forecast period.
  • By mode of operation, the batch segment led the market in 2024.
  • By mode of operation, the perfusion segment is expected to grow at the fastest CAGR in the market during the studied years.
  • By compatibility with bioprocessing systems, the single-use segment held the largest revenue market share in 2024.

Key Metrics and Overview

Metric Details
Market Size in 2025 USD 6.05 Billion
Projected Market Size in 2034 USD 16.88 Billion
CAGR (2025 - 2034) 12.04%
Leading Region North America
Market Segmentation By type of controllers, By scale of operation, By Mode of Operation, By compatibility with the bioprocessing system, By Regions
Top Key Players Merck KGaA, Sartorius, Corning, Danaher, Thermo Fisher, Emerson, Eppendorf, 3Bar Biologics, Lonza Group AG

How is Innovation Impacting the Bioprocess Automation Market?

Bioprocess automation is the integration of automated technologies, control systems, and software to manage, monitor, and optimize biological production processes such as fermentation, cell culture, and downstream processing, ensuring consistency, efficiency, scalability, and compliance with regulatory standards. The market is growing due to increasing demand for efficient and consistent production of biologics and vaccines. The integration of Artificial intelligence, machine learning, and digital twins enables real-time monitoring, predictive maintenance, and process optimization, enhancing efficiency and reducing operational costs. Automation minimizes human error, ensures regulatory compliance, and accelerates time-to-market for biopharmaceutical products. Additionally, the adoption of single-use systems and modular platforms offers scalability and flexibility, catering to the growing demand for personalized medicine and sustainable manufacturing practices.

 For Instance,

  • In February 2025, The Cultivated B launched AI-powered multi-channel biosensors for real-time monitoring of cell culture and fermentation. These sensors offer high-resolution, inline data without manual sampling, reducing contamination risk and improving process consistency. They enhance visibility, accuracy, and decision-making for bioprocess engineers (Source - Cultivate B)
  • In July 2024, Nirrin Technologies introduced Atlas, an at-line analysis system that delivers quick, actionable data on buffer components and product titers in under a minute. Using HPTLS technology, Atlas helps overcome common bottlenecks in biomanufacturing, providing scientists with greater control and enabling faster drug development by reducing delays linked to traditional lab testing. (Source - nirrin)
  • In June 2024, at Achema, Syntegon's subsidiary Pharmatec introduced its Modular Bioprocessing Platform (MBP), a versatile and fully integrated solution for biopharmaceutical manufacturing. Designed to support both microbial and mammalian cell cultures, the MBP aims to reduce lead times and costs while maintaining high quality, offering manufacturers a streamlined and efficient production approach. (Source - SYNTEGON)

How is AI enhancing advancements in the Bioprocess Automation Market?

AI is significantly advancing the market by enabling real-time monitoring, predictive analytics, and intelligent process control. It helps identify patterns, optimize parameters, and detect deviations early, leading to increased efficiency and reduced risk of errors. AI-driven models also accelerate decision-making and improve batch consistency, ultimately enhancing product quality. By automating complex tasks and adapting to dynamic conditions, AI supports faster development cycles and greater scalability in biopharmaceutical manufacturing.

Market Dynamics

Driver

Rising Demand For Biologics

The rising demand for biologics is a major driver in the bioprocess automation market because biologics require complex and precise manufacturing processes. Automation ensures consistent product quality, reduces human error, and increases production efficiency, crucial for meeting growing global needs. As therapies like monoclonal antibodies, vaccines, and cell/gene treatment become more prevalent, automated systems help scale up production while maintaining compliance with regulatory standards, making them essential for the efficiency of biological medicine.

For Instance,

  • In 2024, the Indian government introduced the BioE3 Policy to boost high-performance biomanufacturing. The policy promotes automation and AI integration in bioprocessing through Bio-AI hubs and foundries, aiming to enhance efficiency, support innovation, and strengthen India’s global biotech position. (Source - Azadi ka Amrit Mahotsav)

Restraint

Complex Integration

Complex integration is a major factor in the bioprocess automation market, aligning new automated systems with existing legacy infrastructure is technically challenging and time-consuming. Many biomanufacturing facilities operate with outdated equipment, making compatibility an issue. This often requires extensive customization, increased downtime, and higher implementation costs. Additionally, ensuring seamless data flow across various platforms and maintaining regulatory compliance during integration adds to the complexity, discouraging companies from adopting automation quickly.

Opportunity

Integration of AI and Machine Learning

The integration of AI and machine learning is a major factor that acts as a future opportunity in bioprocess automation because it enables intelligent data-driven process control. These technologies allow real-time monitoring, predictive maintenance, and automated decision-making, improving efficiency, consistency, and product quality. As bioprocesses become more complex, especially in personalized medicine and gene therapies, AI can adapt to dynamic conditions, reduce human error, and accelerate development timelines, making it a valuable asset for next-generation biomanufacturing.

For Instance,

  • In September 2024, Generate: Biomedicines secured a partnership with Novartis, potentially worth over $1 billion, to leverage its generative AI platform for the development of protein therapeutics.  This collaboration underscores the growing importance of AI-driven approaches in accelerating bioprocess development and scaling.  (Source - businesswire)

Segmental Insights

How Upstream Controllers Segment Dominates the Bioprocess Automation Market in 2024?

In 2024, the upstream controller segment held the largest revenue share in the bioprocess automation market due to its critical role in managing early-stage processes like cell culture and fermentation. These stages require precise control of parameters such as pH, temperature, and dissolved oxygen to ensure optimal cell growth and product yield. Automation in upstream processes enhances consistency, reduces variability, improves overall productivity, and propels market growth.

The bioprocess controller segment is projected to grow rapidly as the industry shifts towards fully connected, intelligent manufacturing systems. These controllers enable seamless coordination of multiple process stages, improving operational efficiency and data accuracy, with the growing complexity of biologics production, there is a rising need for smart systems that can adapt in real-time, reduce manual intervention, and support automation across the entire production cycle, making bioprocess controllers a vital investment for modern facilities.

Why Did the Preclinical Segment Dominate in the Bioprocess Automation 2024?

The preclinical segment dominated the bioprocess automation market due to the increasing focus on early-stage drug development and the need for rapid, cost-effective testing of biologics. Automation at this stage enhances experiment accuracy, reduces manual errors, and accelerates data collection, enabling faster decision-making. With rising investments in R&D and a surge in biotech startups, demand for flexible, small-scale automated systems in preclinical research has grown, making it the leading segment by scale of operation.

The commercial segment is expected to grow at the fastest CAGR due to the rising demand for large-scale production of biologics and biosimilars. As more therapies receive regulatory approval, biopharma companies are scaling up manufacturing to meet global needs. Automation in commercial operations ensures consistent quality, reduces production costs, and supports high-volume output. The push for efficiency, compliance, and reduced time-to-market in large-scale facilities is driving greater adoption of advanced bioprocess automation solutions.

What Made the Batch Suites the Dominant Segment in 2024?

In 2024, the batch segment led the bioprocess automation market due to its widespread use in producing biologics, where consistent quality and strict control over each production cycle are essential. Batch processing allows better traceability, easier validation, and compliance with regulatory standards, making it ideal for high-value, low-volume products like vaccines and monoclonal antibodies. Its established infrastructure and reliability make it the preferred choice for many biopharma manufacturers, contributing to its market dominance.

The perfusion segment is expected to grow at the fastest CAGR due to its ability to support continuous bioprocessing with higher cell densities and consistent product quality. Unlike traditional batch methods, perfusion allows for the steady removal of waste and the addition of nutrients, enabling longer production runs and improved yields. As demand rises for efficient and scalable biologic production, especially for complex therapies, perfusion systems are becoming increasingly attractive for their productivity and cost-effectiveness.

How Single-use Segment Dominates the Market?

The single-use segment held the largest revenue share in the bioprocess automation market due to its flexibility, lower risk of cross-contamination, and reduced cleaning and sterilization requirements. These systems are ideal for small-batch and multi-product facilities, offering faster setup times and easier scalability. As biologics and personalized medicines gain momentum, manufacturers prefer single-use technologies for their efficiency, cost savings, and compliance with strict regulatory standards, making them a dominant choice in automated bioprocessing setups.

How is North America Contributing to the Expansion of the Bioprocess Automation Market?

North America dominated the market in 2024 due to its strong presence of leading biopharmaceutical companies, advanced R&D infrastructure, and high adoption of innovative technologies. Significant investments in biologics, personalized medicine, and automation solutions, along with supportive regulatory frameworks, have accelerated market growth. Additionally, the region's focus on improving manufacturing efficiency and increasing demand for high-quality therapeutics has driven the widespread implementation of automated bioprocessing systems across research and commercial facilities.

The U.S. Bioprocess Automation Market Trends

The country's strong biopharmaceutical sector, with significant investments in R&D and advanced manufacturing, drives demand for automation to enhance efficiency and product quality.  Additionally, the rise of personalized medicine and biologics necessitates precise, scalable production processes, which automation facilitates.  Supportive regulatory frameworks and technological innovations further contribute to the market's growth, positioning the U.S. as a leader in bioprocess automation adoption.

The Canada Bioprocess Automation Market Trends

The Canadian market is experiencing significant growth due to robust government support and strategic investments in biotechnology infrastructure.  Initiatives like the Strategic Innovation Fund have been instrumental in funding large-scale projects, such as the $62 million investment in Entos Pharmaceuticals' facility in Edmonton, which focuses on producing generic medicines. These efforts aim to enhance domestic biomanufacturing capabilities, reduce reliance on imports, and foster innovation in the life sciences sector.

How is Asia-Pacific approaching the Bioprocess Automation Market in 2025?

The Asia-Pacific region is poised for rapid growth in the market due to several key factors. Countries like China and India are heavily investing in biotechnology research and expanding biopharmaceutical manufacturing capabilities.  Government initiatives promoting local biomanufacturing, coupled with the rising demand for affordable biologics, are driving the adoption of advanced bioprocessing technologies.  Additionally, the integration of digitalization and innovative solutions in upstream bioprocessing is enhancing flexibility and cost-effectiveness, further propelling market expansion in the region. 

The China Bioprocess Automation Market Trends

China's market is expanding due to significant investments in biomanufacturing infrastructure and a growing emphasis on innovative therapies.  The country's focus on developing advanced biologics and enhancing production capabilities has attracted global partnerships and investments.  Additionally, the adoption of automation technologies is streamlining processes, improving efficiency, and reducing costs, positioning China as a key player in the global biopharmaceutical landscape. 

The India Bioprocess Automation Market Trends

India's market is expanding due to a combination of government initiatives, a robust pharmaceutical sector, and a growing biotechnology ecosystem.  The government's Bio-RIDE scheme, launched in 2024, aims to advance biomanufacturing and foundries, fostering innovation in the sector.  Additionally, India's pharmaceutical industry, being one of the largest globally, is increasingly adopting automation to enhance efficiency and meet global standards.  The rise in biotech startups and increased R&D investments further contribute to the market's growth. 

How is Europe Accelerating the Bioprocess Automation Market?

Europe is accelerating the market through strategic initiatives and investments aimed at enhancing biomanufacturing capabilities.  The European Commission's 2024 initiative focuses on streamlining regulatory pathways, ensuring access to sustainable feedstocks, and fostering innovation in biotechnology and biomanufacturing. Additionally, the establishment of specialized training centers, such as the Biotech Campus Delft and the EU Biotech Campus in Belgium, supports workforce development and knowledge transfer. These efforts are designed to bolster Europe's competitiveness in the global biomanufacturing sector.

The UK Bioprocess Automation Market Trends

The UK market is growing due to strong government support, including funding programs like Innovate UK's £1.9 million grant for digital bioprocess development. Collaborative efforts between academia and industry, such as the Cell and Gene Therapy Catapult, drive innovation. Additionally, the adoption of advanced technologies like single-use systems and AI-based process optimization improves efficiency and scalability, collectively boosting the market's expansion.

For Instance,

  • The UK government’s collaboration with Moderna to set up a vaccine production and R&D facility highlights its commitment to strengthening global biomanufacturing. This investment supports innovation in bioprocess control, including areas like fermentation and analytical technologies, laying the groundwork for future advancements.

The Germany Bioprocess Automation Market Trends

Germany’s market is growing due to its strong biotech infrastructure, with leading companies driving innovation in automation and continuous processing. Government initiatives support biomanufacturing advancements and competitiveness. Additionally, increasing demand for biologics and biosimilars pushes manufacturers to adopt automated systems for improved efficiency and scalability. These combined factors are accelerating the expansion of Germany’s bioprocess automation sector.

Top Companies in the Bioprocess Automation Market

Bioprocess Automation Market Companies

Latest Announcement by Industry Leaders

In March 2025, Prendio-BioProcure launched new AI-powered procurement tools tailored for biotech firms. These features aim to cut costs, automate workflows, and enhance supplier insights, helping R&D teams focus more on innovation. By simplifying procurement and reducing admin work, the platform supports biotech companies in extending their financial runway and accelerating scientific progress. (Source - PR Newswire)

Recent Developments in the Bioprocess Automation Market

  • In December 2024, Sartorius Stedim Biotech launched its Center for Bioprocess Innovation in Marlborough, Massachusetts. The new facility is designed to support collaboration with clients and partners, with a focus on improving bioprocessing methods for cell and gene therapies. The center aims to boost manufacturing efficiency and lower costs for next-generation treatments. (Source - Sartorius)
  • In November 2024, New Wave Biotech introduced Bioprocess Foresight, an AI-driven simulation tool designed for the alternative protein sector. This platform helps innovators optimize process design, speed up commercialization, and scale operations sustainably. It offers detailed insights into costs, productivity, and environmental impact, enabling users to explore different process strategies and pinpoint critical R&D areas. (Source - NEW WAVE BIOTECH)

Segments Covered in the Report

By type of controllers

  • Upstream controllers
  • Downstream controller
  • Bioprocess control software

By scale of operation

  • Preclinical
  • Clinical operations
  • Commercial operations

By Mode of Operation

  • Batch
  • Fed-batch
  • Perfusion

By compatibility with the bioprocessing system

  • Single-use systems
  • Stainless steel
  • Other systems

By Region

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Thailand
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
OSZAR »
  • Last Updated: 06 June 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

Meet the Team

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and strategy.

Learn more about Shivani Zoting

Aditi Shivarkar, with over 14 years of experience in consumer goods, leads research at Towards Consumer Goods, ensuring precise, actionable insights on trends, consumer preferences, and sustainable packaging for businesses.

Learn more about Aditi Shivarkar

Related Reports

FAQ's

Primarily used in biotechnology and pharmaceutical industries, especially in the production of biologics, vaccines, biosimilars, and cell & gene therapies.

AI improves process prediction, anomaly detection, and optimization by analyzing large datasets in real-time, supporting smarter decision-making and faster development cycles.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.
OSZAR »